The new year has come, and Abbott Labs' spinoff of its branded pharmaceuticals division into the new company AbbVie is complete. AbbVie is getting all of the attention from analysts at the moment because of its powerhouse arthritis drug, Humira, which generates the bulk of the revenue for the company -- but what about Abbott Labs? In this video, Motley Fool health care bureau chief Brenton Flynn tells us what he thinks of the trimmer new Abbott sans the branded pharmaceuticals, and why it reminds him a lot of Johnson & Johnson .
Want to know more about that new position in your portfolio? To help investors better understand the situation with both Abbott Labs and AbbVie, The Fool has created a brand new premium report on both stocks. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now.
Copyright © 2009 The Motley Fool, LLC. All rights reserved.